ES2181298T3 - Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos. - Google Patents

Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos.

Info

Publication number
ES2181298T3
ES2181298T3 ES98955056T ES98955056T ES2181298T3 ES 2181298 T3 ES2181298 T3 ES 2181298T3 ES 98955056 T ES98955056 T ES 98955056T ES 98955056 T ES98955056 T ES 98955056T ES 2181298 T3 ES2181298 T3 ES 2181298T3
Authority
ES
Spain
Prior art keywords
thyroxine
tumors
hormonal activity
ketone
evil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98955056T
Other languages
English (en)
Inventor
Ernest Kun
Jerome Mendeleyev
Kalman G Buki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octamer Inc filed Critical Octamer Inc
Application granted granted Critical
Publication of ES2181298T3 publication Critical patent/ES2181298T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Utilización de un análogo de cetona tiroxina que tiene la fórmula siguiente para la preparación de un medicamento para el tratamiento de un tumor maligno sensible a los compuestos siguientes en un mamífero, presentando dicho análogo de cetona tiroxina una actividad hormonal significativa y siendo un compuesto capaz de inhibir la velocidad inicial del conjunto de la proteína microtubular in vitro: **fórmula** y sus sales farmacéuticamente aceptables, en la que: X = O, S, CH2, carboxi o ausente; Y = O ó S; R1 = metil ó etil; R2, R3, R4 y R5 se seleccionan independientemente de entre el grupo que consta de: H, alquil C1-C4, alquenil C1-C4, alquinil C1-C4, hidroxil, alcoxi C1-C4 y halógeno; R6, R7, R8 y R9 se seleccionan independientemente de entre el grupo que consta de: H, alquil C1-C4, alquenil C1-C4, alquinil C1-C4, hidroxil, alcoxi C1-C4, halógeno, NO2 y NH2; y R10 se selecciona de entre el grupo que consta de alquil C1-C4, alquenil C1-C4 y alquinil C1-C4.
ES98955056T 1997-10-23 1998-10-23 Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos. Expired - Lifetime ES2181298T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/956,711 US5922775A (en) 1997-10-23 1997-10-23 Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity

Publications (1)

Publication Number Publication Date
ES2181298T3 true ES2181298T3 (es) 2003-02-16

Family

ID=25498590

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98955056T Expired - Lifetime ES2181298T3 (es) 1997-10-23 1998-10-23 Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos.

Country Status (7)

Country Link
US (1) US5922775A (es)
EP (1) EP1024800B1 (es)
AT (1) ATE222489T1 (es)
AU (1) AU1195499A (es)
DE (1) DE69807349T2 (es)
ES (1) ES2181298T3 (es)
WO (1) WO1999020263A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6433012B1 (en) * 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
AU3109199A (en) * 1998-03-25 1999-10-18 Large Scale Biology Corporation Benzoates derivatives for inhibiting angiogenesis
US6326402B1 (en) * 1998-08-12 2001-12-04 Octamer, Inc. Methods for treating viral infections using a compound capable of inhibiting microtubules
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2007292302A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
CN103169973A (zh) 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
KR20190126074A (ko) * 2017-02-03 2019-11-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 레티쿨론 4를 억제하기 위한 조성물 및 방법
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US20230141913A2 (en) * 2018-08-24 2023-05-11 Xeniopro GmbH Phenoxy(hetero)aryl ethers of antiproliferactive activity
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB643089A (en) * 1947-10-23 1950-09-15 Glaxo Lab Ltd Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers
GB642159A (en) * 1947-10-23 1950-08-30 Glaxo Lab Ltd Improvements in or relating to the preparation of diphenyl ethers
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
GB9211415D0 (en) * 1992-05-29 1992-07-15 Ici Plc Process for the production of purified terephthalic acid
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Also Published As

Publication number Publication date
AU1195499A (en) 1999-05-10
WO1999020263A1 (en) 1999-04-29
DE69807349D1 (de) 2002-09-26
ATE222489T1 (de) 2002-09-15
DE69807349T2 (de) 2003-01-02
EP1024800A1 (en) 2000-08-09
US5922775A (en) 1999-07-13
EP1024800B1 (en) 2002-08-21

Similar Documents

Publication Publication Date Title
ES2181298T3 (es) Analogos de tiroxina que poseen una actividad hormonal no significativa para el tratamiento de tumores malignos.
DK0954299T3 (da) Thyroxin-analoger uden signifikant hormonal aktivitet til behandling af ondartede tumorer
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
BR0112038A (pt) Triazolopirimidinas substituìdas como agentes anticâncer
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
ES2068705T3 (es) Tratamiento de la enfermedad neoplastica con interleuquina-10.
DE69724682D1 (de) Verwendung von Gonadotropin releasing Hormon Analogen oder änlichen Verbindungen zur Herstellung von pharmazeutischen Zubereitungen als Zusatz für invasiver Behandlung von Karzinomen
DE60233261D1 (de) Inhibitoren von humanem adam-10
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
NO994330L (no) Metode for behandling av en tumor
WO2023164455A3 (en) Compositions and methods to modulate the immune system
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
SE9601396D0 (sv) New therapeutic treatment 2
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.
SE9601395D0 (sv) New therapeutic treatment 1